The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study.
Jean-François Flejou
Research Funding - Genomic Health; Sanofi
Thierry André
Consultant or Advisory Role - Genomic Health
Honoraria - Sanofi
Research Funding - Genomic Health; Sanofi
Benoist Chibaudel
Honoraria - Sanofi
Aurelie Scriva
No relevant relationships to disclose
Tamas Hickish
Research Funding - Sanofi
Josep Tabernero
Honoraria - Sanofi
Jean-Luc Van Laethem
No relevant relationships to disclose
Maria Banzi
No relevant relationships to disclose
Eduard Maartense
No relevant relationships to disclose
Adi Shani
No relevant relationships to disclose
Göran Carlsson
No relevant relationships to disclose
Werner Scheithauer
No relevant relationships to disclose
Demetris Papamichael
No relevant relationships to disclose
Markus Moehler
No relevant relationships to disclose
Stefania Landolfi
No relevant relationships to disclose
Pieter Demetter
No relevant relationships to disclose
Alex Duval
No relevant relationships to disclose
Mark Lee
Employment or Leadership Position - Genomic Health
Soudhir Colote
Honoraria - Sanofi
Aimery De Gramont
Consultant or Advisory Role - Genomic Health
Honoraria - Sanofi
Research Funding - Genomic Health; Sanofi